NCT03686124 2026-02-18
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT03947385 2026-01-27
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT04130516 2025-12-18
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Linnaeus Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06940739 2025-12-03
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Iovance Biotherapeutics, Inc.
Phase 1/2 Recruiting
NCT06961357 2025-12-03
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
NCT07136181 2025-11-28
NBM-BMX-UM
Novelwise Pharmaceutical Corporation
Phase 1/2 Recruiting
NCT06784648 2025-11-19
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
BioInvent International AB
Phase 1/2 Active not recruiting
NCT05893654 2025-09-15
MELCOM
Hospital das ClÃnicas de Ribeirão Preto
Phase 1/2 Enrolling by invitation
NCT04283890 2025-09-09
CHOPIN
Leiden University Medical Center
Phase 1/2 Active not recruiting
NCT05415072 2025-07-20
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Novartis
Phase 1/2 Active not recruiting
NCT07063875 2025-07-14
SILVER
St Vincent's Hospital, Sydney
Phase 1/2 Recruiting